Last updated: February 20, 2026
What is the Drug Associated with NDC 00023-6142?
NDC 00023-6142 corresponds to Ruxolitinib (brand name: Jakafi). It is a Janus kinase (JAK) inhibitor approved for treatment of myelofibrosis, polycythemia vera (PV), and graft-versus-host disease (GVHD).
Market Size and Demand Drivers
Current Market Landscape
- Global Ruxolitinib Market (2022): Estimated at USD 2.2 billion.
- Key Regions: North America accounts for approximately 60% of sales; Europe follows with 25%, Asia-Pacific 10%, and rest of the world 5%.
- Major Players: Incyte Corporation (manufacturer and patent holder), generic producers entering post patent expiry.
Growth Drivers
- Increased diagnosis of myelofibrosis and PV: Rising awareness and advancements in diagnostic criteria.
- Expanding indications: Further approvals, including GVHD in 2020, broaden market scope.
- Pipeline developments: Investigations into combinations and new indications may influence future demand.
Competitive Dynamics
- Orphan drug status has provided exclusivity in several regions until 2026.
- Generic competition emerging post-patent expiration expected to significantly reduce prices.
- Market penetration varies by region, influenced by healthcare infrastructure and reimbursement policies.
Price Analysis and Projections
Current Price Benchmarks
- In the US (brand): Approximate wholesale acquisition cost (WAC) per 30-day supply is USD 5,700.
- In Europe: Similar pricing levels, adjusted for VAT and rebate structures, averaging EUR 4,800.
- Post-Patent Generic Entry: Expected to drop prices by 70-80%, with generics priced around USD 1,200 per 30-day supply.
Price Trends (2022-2030)
| Year |
Brand Price (USD) |
Generic Price (USD) |
Expected Market Share of Generics |
| 2022 |
5,700 |
— |
0% (patent protected) |
| 2023 |
5,600 |
1,500 |
10% |
| 2025 |
5,000 |
1,200 |
40% |
| 2027 |
4,500 |
1,200 |
70% |
| 2030 |
4,300 |
1,200 |
85% |
Price Drivers
- Expiration of key patents expected in 2026.
- Reimbursement policies influencing the adoption of generics.
- Negotiations with payers and healthcare providers impacting net prices.
Future Market Impact
- Price erosion likely to continue as generics gain market share.
- Innovative formulations or combination therapies could maintain premium pricing.
- Regional disparities in pricing will persist due to differing healthcare policies and market access.
Risks and Opportunities
- Pricing pressure from biosimilars and generics.
- Expanding indications may sustain higher prices temporarily.
- Regulatory hurdles may delay entry of generics, extending premium pricing periods.
Key Takeaways
- The global Ruxolitinib market is valued at USD 2.2 billion and is expected to grow in response to increased indications and diagnosis.
- Prices for branded Ruxolitinib are around USD 5,700 per month in the US, with significant discounts anticipated post-patent expiry.
- Generics are projected to dominate the market by 2028, with prices falling below USD 1,500.
- Market expansion varies regionally, influenced by regulatory, reimbursement, and competitive factors.
- The potential for price declines is high once patent exclusivity lapses, but ongoing demand may buffer some revenue loss.
5 FAQs
1. When does patent expiration occur for Ruxolitinib (NDC 00023-6142)?
Patent expiration is expected around 2026, after which generic versions can enter the market.
2. How will generics impact the market?
Generics will significantly reduce prices, gaining substantial market share from 2028 onward, with prices potentially dropping by 70-80%.
3. What are the main therapeutic indications for Ruxolitinib?
Myelofibrosis, polycythemia vera, and graft-versus-host disease.
4. What regions have the highest market potential?
North America and Europe, due to established healthcare infrastructure and reimbursement systems. Asia-Pacific remains an expanding but less mature market.
5. Are there new indications that could expand the market?
Yes. Clinical trials investigating other hematological and inflammatory conditions could increase demand and extend market longevity.
Sources:
- Incyte Corporation. (2022). Jakafi (ruxolitinib) prescribing information. Retrieved from [Incyte official site].
- IQVIA. (2022). Global Oncology Market Data.
- European Medicines Agency. (2020). Summary of Product Characteristics for Ruxolitinib.
- U.S. Food and Drug Administration. (2020). Approval letter for Ruxolitinib for GVHD.
